Omega Funds

Omega Funds is a prominent global investment firm dedicated exclusively to the life sciences sector, headquartered in Geneva, Switzerland. Established with a deep focus on drug development, the firm employs a versatile investment strategy that spans from company creation and early-stage ventures to later-stage private and public companies, including specialized direct secondary transactions. With a substantial capital base, Omega Funds manages over $2.4 billion in assets, positioning itself as a significant player in the biotech and pharmaceutical investment landscape.

The firm's investment philosophy centers on a hands-on, company-building approach, leveraging its extensive industry expertise and network to support the growth and success of its portfolio companies. Omega Funds invests across the entire spectrum of drug development, from preclinical research through clinical trials and commercialization. Their commitment to the sector is underscored by their successful fundraising efforts, including the close of Omega Fund VII at $670 million in 2021, which followed Omega Fund VI at $507 million in 2018. Since its inception, Omega Funds has invested in over 65 companies, demonstrating a consistent track record of identifying and nurturing innovative life science enterprises.

Given the capital-intensive nature of drug development, Omega Funds is equipped to make substantial investments. While their strategy encompasses various stages, typical first cheques for their primary investments often range from $10 million for early-stage company creation or Series A rounds, extending up to $75 million for significant Series B, C, or direct secondary transactions. This broad range allows them to be a lead investor in substantial financing rounds, providing the necessary capital for ambitious drug development programs. Their global reach and specialized focus make them a key partner for life science innovators seeking significant funding and strategic guidance.